Navigation Links
Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
Date:3/23/2011

and Mexico once the product is approved in these countries. Amgen will commercialize Prolia's postmenopausal osteoporosis and potential oncology indications in the U.S. and Canada and for all oncology indications in Europe and in other specified markets.

In addition, GlaxoSmithKline will register and commercialize denosumab for all indications in countries where Amgen does not currently have a commercial presence, including China, Brazil, India and South Korea but excluding Japan. The structure of the collaboration allows Amgen the option of an expanded role in commercialization in both Europe and certain emerging markets in the future.

Amgen and Daiichi-Sankyo Company Limited have a collaboration and license agreement for the development and commercialization of denosumab in Japan.

About AmgenAmgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.

Forward-Looking StatementsThis news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking stateme
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
2. Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies
3. AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation
4. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
5. The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant
6. Los Angeles Dentist, Dr. Kevin Sands, Uses the Latest Technologies to Provide VIP Services and Treatments for His Patients
7. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
8. Practice Guidelines Confirm Utility of Endoscopic Radiofrequency Ablation (RFA) for the Treatment of Barretts Esophagus
9. Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act of 2011
10. Tris Announces NDA Acceptance of Extended Release Carbinoxamine Oral Suspension for the Treatment of Allergies in Kids Two Years and Older
11. Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 Investor-Edge ... (NASDAQ: NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, ...
(Date:10/31/2014)... (OTCQB:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2015 ... Company posted quarterly net revenue of $2.279 million for ... per share. These results compare to net revenue of ... or $(0.01) per share, in the year-ago quarter. Gross ...
(Date:10/31/2014)... 2014 Research ... of the  "Process Validation in the US and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to ... Approach to Process Validation for Pharmaceutical and Biopharmaceutical ... FDA Process Validation Guidance EU Process ...
Breaking Medicine Technology:Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... The U.S. Food and Drug Administration today issued draft ... previously cleared 510(k) device require a new premarket submission. ... The 510(k) process is the most common review path ... a device, manufacturers must submit a premarket notification or ...
...   UK pharma group ... quarter but highlights strong underlying sales momentum. ... CEO Andrew Witty and CFO Simon Dingemans review Q2 ... strategy, improving margins and a review of the recently ...
Cached Medicine Technology:FDA Issues Draft Guidance on Device Changes That Warrant New Premarket Review 2
(Date:10/31/2014)... October 31, 2014 — A team from the ... the University of California, Santa Cruz, was awarded ... Genomics Cloud Pilot contracts with the goal of ... of The Cancer Genome Atlas (TCGA) and other ... computing resources in one cloud environment. This co-location ...
(Date:10/31/2014)... October 31, 2014 Daily Gossip writes in ... actually described as the fastest fat loss program ever developed. ... than a month. , There is no wonder after all ... of all time. The new nutrition and workout fat loss ... fitness expert. , According to the author of this ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 This ... has amazing health effects for practitioners. , ... a Doctor of Science and Movement specializing in ... dedication to pelvic floor reeducation that traditional abdominal ... incontinence, Diastasis Recti, Prolepses, etc. , The Hipopressives ...
(Date:10/31/2014)... Joseph, Missouri (PRWEB) October 31, 2014 ... for school, one Midwest optometrist feels they may overlook ... problems to affect areas like concentration, school performance and ... may be too brief to identify progressive vision problems, ... St. Joseph, Mo., announces a new initiative: The Awesome ...
(Date:10/31/2014)... Energy Textiles has recently added a new ... now available online, and Energy Textile is providing their ... athletic gear over compression gear. , The Boston ... signed for Under Armour to provide team gear for ... In light of this decision, Energy Textiles contemplates whether ...
Breaking Medicine News(10 mins):Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4
... a non-profit organization focused on supporting innovative early ... at its fall Fellowship Award Committee review. ... outstanding postdoctoral scientists conducting basic and translational cancer ... across the country. The Fellowship encourages the nation,s ...
... Mozes HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... amounts of vigorous physical exercise appear to lower their risk ... hours a week or more of vigorous biking, tennis, jogging ... the research team found. But they added that even moderate ...
... 5 (HealthDay News) -- The number of American adults treated for ... 9 million to 19 million, says a federal government report released ... diabetes increased from 4.3 million to 8 million among people age ... 45 to 64; and 1.2 million to 2.4 million among people ...
... Gehrig,s disease, or amyotrophic lateral sclerosis (ALS), and frontotemporal ... brain and spinal-cord cells that include an RNA-binding protein ... of the lesions formed by these clumps. ... Clinical Investigation , a team led by Virginia M.-Y. ...
... HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay News) ... be treatable with a vaccine that has been engineered ... with a cocaine-like substance that mimics cocaine,s molecular composition. ... effective and long-lasting antibody immune response, attacking cocaine molecules ...
... at Mount Sinai School of Medicine has developed the ... This instrument has recently been used by soldiers returning ... in the Sixth Annual Road to Recovery Conference and ... TBI. "Traumatic brain injury is underdiagnosed, and ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 4Health News:Exercise May Improve Odds Against Prostate Cancer Death 2Health News:Exercise May Improve Odds Against Prostate Cancer Death 3Health News:Exercise May Improve Odds Against Prostate Cancer Death 4Health News:Diabetes Soaring Among American Adults: Report 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 3Health News:Mount Sinai develops first screening tool for war veterans to assess traumatic brain injury 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: